The third time was the charm for Amylin Pharmaceuticals‘ once-a-week diabetes injection drug. Bydureon was approved Friday, following two prior rejections. Amylin executives say the new drug’s convenient regimen will give it a competitive advantage in the marketplace. Diabetes affects more than 25 million people in the U.S., including many nursing facility residents.
Please login or register first to view this content.